The information on this page applies only to the United States
Through new product development, growth of existing brands, strategic acquisitions and collaborative relationships Valeant has established itself as one of the largest prescription dermatology companies in the world and the leader in the U.S. medical dermatology market. We continue to build a broad portfolio offering across a number of categories in this fast-growing segment.
Our dermatology products help patients in the treatment of a range of therapeutic areas including actinic keratosis, acne, atopic dermatitis, cold sores, athlete’s foot, nail fungus and other dermatoses. Our portfolio includes a number of leading acne, anti-fungal and anti-infective products.
Underscoring Valeant’s strong leadership position is our unwavering customer focus. Physicians prefer trusted manufacturer brands and through our expanded sales force, we are building critical relationships with, and providing support for, physicians. Our dermatology portfolio also complements other existing Valeant platforms, including aesthetics and consumer healthcare.
Our pipeline continues to be a prolific source of new products and we have several important new products lined up for upcoming launches. One major product from our pipeline, approved in 2014 by the U.S. FDA, is Jublia®, a topical anti-fungal for the treatment of onychomycosis (fungal infection of the nails), for which there is a significantly large market.
Other key Valeant products include Luzu™ (athlete’s foot), Solodyn®, Retin-A Micro® Gel 0.08% and Acanya® Gel (acne), Zyclara® (actinic keratoses) and Elidel® (dermatitis).